I am what I am! LGBT History Month

By Mike Beaman, FRPharmS, retired pharmacist

I am writing this blog in support of the Royal Pharmaceutical Society’s response to LGBT History Month.  Although not a gay activist I have, nevertheless, been generally open about my lifestyle since coming to terms with being a gay man back in the early 1970s.

I was born in 1947 so I was 19 and a university undergraduate when the legislation decriminalising homosexuality became law in 1967. I was already a young adult and therefore having an intimate relationship with another man before that time would have been a criminal act and would also have resulted in my being sent down from university and unable to eventually register as a pharmacist. Read more I am what I am! LGBT History Month

Veterinary medicines – Use them or lose them?

By Rob Morris, FRPhamS, Chair of the RPS Veterinary Pharmacy Forum

In case you didn’t know, pharmacists are in a very privileged position when it comes to the supply of veterinary medicines in the UK. Unlike human medicines, the animal equivalents are regulated and licensed by the Veterinary Medicines Directorate (VMD) – an executive agency sponsored by DEFRA.

Whilst the vast majority of vet medicines are handled by veterinary surgeons, animal health merchants and pet stores, the VMD still regards pharmacists a key supplier to both the farm and pet-owning public. Animal health merchant and pet store owners must ensure they have appropriately trained staff, or Suitably Qualified Persons (SQPs) and also operate from licensed premises which the VMD duly inspect and regulate – rather like our GPhC. The VMD are satisfied that pharmacists already have the appropriate professional knowledge, training and regulation so they do not interfere. Read more Veterinary medicines – Use them or lose them?

Biosimilar adalimumab is a test of shared decision making in the NHS

Co-written by the National Rheumatoid Arthritis Society, National Ankylosing Spondylitis Society, RNIB, Birdshot Uveitis Society, Psoriasis Association and Crohn’s & Colitis UK

The entry of new biosimilars and the creation of an NHS ‘local market of treatment options’ will see significant numbers of patients switched from the originator product, Humira, to one of four biosimilar alternatives this year.

Adalimumab is one of several biological drugs used in the treatment of autoimmune inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, non-infectious posterior uveitis, Crohn’s and colitis.

While some patients will take this in their stride, for others the change will be met with feelings of apprehension. Read more Biosimilar adalimumab is a test of shared decision making in the NHS

Polypharmacy – what is it and why is it important?

By Clare Howard, FFRPS FRPharmS, lead author of the RPS guidance Polypharmacy: getting our medicines right

What is polypharmacy?
We know that medicines have an enormous, positive impact on the lives of millions of people. But as more of us live longer, with multiple long-term conditions, we take more and more medicines. Taking many different medicines at once can become either a practical challenge or increase the likelihood of harm, or both.

Problems with polypharmacy happen when: 
• Medicines are prescribed that are no longer clinically indicated, appropriate or optimised for that person
• The harm of a particular medicine outweighs the benefit
• The combination of medicines being taken has the potential to, or is actually causing harm to the person
• Where the practicalities of using the medicines have become unmanageable or are causing harm or distress.  Read more Polypharmacy – what is it and why is it important?